BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12174320)

  • 1. Before oral agents fail: the case for starting insulin early.
    Marre M
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S25-30. PubMed ID: 12174320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO; Lindström T
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin therapy in type 2 diabetes: what is the evidence?
    van Avendonk MJ; Rutten GE
    Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM; Bergstad I; Thorsby PM; Johannesen O; Solberg M; Birkeland KI
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period.
    Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W
    J Am Osteopath Assoc; 1996 Jun; 96(6):346-51. PubMed ID: 8690621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive insulin regimens: evidence for benefit.
    Bretzel RG
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S8-13. PubMed ID: 15306832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes.
    Sinagra D; Scarpitta AM; Amato M
    Eur Rev Med Pharmacol Sci; 1998; 2(5-6):175-9. PubMed ID: 10710815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.
    Goudswaard AN; Furlong NJ; Rutten GE; Stolk RP; Valk GD
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD003418. PubMed ID: 15495054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why, when and how to initiate insulin therapy in patients with type 2 diabetes.
    Tibaldi J; Rakel RE
    Int J Clin Pract; 2007 Apr; 61(4):633-44. PubMed ID: 17394436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient.
    Meneghini L
    Int J Clin Pract; 2008 Aug; 62(8):1255-64. PubMed ID: 18705822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin in type 2 diabetes: promises to keep.
    Basu AK; Bandyopadhyay D; Bandyopadhyay R; Majumdar D; Chakrabarty PP
    J Indian Med Assoc; 2004 Aug; 102(8):438, 440, 442 passim. PubMed ID: 15719806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetes mellitus type II: when convert to insulin?].
    Bianda TL; Spinas GA
    Praxis (Bern 1994); 1997 Sep; 86(38):1453-7. PubMed ID: 9381045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
    Hermann LS; Melander A
    Lakartidningen; 1999 Dec; 96(50):5616-9. PubMed ID: 10643226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.